Plain-English translation of NCT06154538 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining immune checkpoint inhibitors with a standard chemotherapy regimen called FOLFOX can help more patients with locally advanced colorectal cancer respond to treatment before surgery. Half of the participants will receive immune checkpoint inhibitors plus chemotherapy, while the other half will receive chemotherapy alone. The goal is to see if the medication helps shrink tumors better and improve survival outcomes.
Colorectal cancer that hasn't spread far can often be treated with surgery, but doctors want to improve how well patients respond to treatment beforehand. This medication works by helping the immune system recognize and fight cancer cells, and researchers believe combining it with chemotherapy might help more patients achieve better results before surgery.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication plus chemotherapy or chemotherapy alone, given intravenously every two weeks. After 3 cycles of treatment (about 6 weeks), imaging scans will check how well the cancer is responding, and if your tumor can be removed, you'll have surgery. If surgery goes well, you may continue with up to 9 total cycles of your assigned treatment before the study ends. Throughout the trial, you'll have regular appointments for imaging, blood tests, and check-ups to monitor how the treatment is working and any side effects.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China